Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.96% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3276
Forte Biosciences
FBRX
$1.57B
| $213K | ﹤0.01% |
8,192
-348
| -4% | -$9.04K |
|
3277
Gain Therapeutics
GANX
$100M
| $213K | ﹤0.01% |
47,600
+8,900
| +23% | +$43.4K |
|
3278
Century Therapeutics
IPSC
$360M
| $213K | ﹤0.01% |
67,300
-85,801
| -56% | -$277K |
|
3279
Midland States Bancorp
MSBI
$703M
| $213K | ﹤0.01% |
10,700
-4,200
| -28% | -$84.7K |
|
3280
Trevi Therapeutics
TRVI
$2.62B
| $213K | ﹤0.01% |
89,300
-148,100
| -62% | -$373K |
|
|
CNTA
3281
DELISTED
Centessa Pharmaceuticals
CNTA
| $212K | ﹤0.01% |
34,300
+18,600
| +118% | +$88.2K |
|
3282
Entegris
ENTG
$25.2B
| $212K | ﹤0.01% |
1,910
-2,600
| -58% | -$237K |
|
3283
First Trust Dorsey Wright Focus 5 ETF
FV
$3.83B
| $211K | ﹤0.01% |
4,500
-14,000
| -76% | -$624K |
|
3284
State Street SPDR Portfolio S&P 400 Mid Cap ETF
SPMD
$19B
| $211K | ﹤0.01% |
+4,600
| New | +$201K |
|
3285
Schwab 1000 Index ETF
SCHK
$5.96B
| $210K | ﹤0.01% |
+9,800
| New | +$198K |
|
3286
Cricut
CRCT
$1.22B
| $209K | ﹤0.01% |
17,100
-18,100
| -51% | -$198K |
|
3287
Skillful Craftsman
EDTK
$14M
| $209K | ﹤0.01% |
155,100
-4,100
| -3% | -$6.75K |
|
3288
First Internet Bancorp
INBK
$258M
| $209K | ﹤0.01% |
+14,100
| New | +$196K |
|
|
JT
3289
DELISTED
Jianpu Technology Inc. American Depositary Shares, each representing twenty Class A Ordinary Shares
JT
| $209K | ﹤0.01% |
189,669
-24,400
| -11% | -$31K |
|
|
WRN
3290
Western Copper and Gold
WRN
$534M
| $208K | ﹤0.01% |
135,700
+94,177
| +227% | +$158K |
|
3291
Direct Digital Holdings
DRCT
$2M
| $207K | ﹤0.01% |
330
-171
| -34% | -$118K |
|
|
RVPH
3292
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $207K | ﹤0.01% |
1,765
+809
| +85% | +$103K |
|
|
VINC
3293
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $207K | ﹤0.01% |
7,955
-1,795
| -18% | -$51.4K |
|
3294
Achieve Life Sciences
ACHV
$733M
| $206K | ﹤0.01% |
39,600
-2,000
| -5% | -$14K |
|
3295
Humacyte
HUMA
$160M
| $205K | ﹤0.01% |
71,600
+23,900
| +50% | +$86.2K |
|
|
SDC
3296
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
| $205K | ﹤0.01% |
386,412
+93,100
| +32% | +$38K |
|
3297
Bank7 Corp
BSVN
$501M
| $204K | ﹤0.01% |
8,300
-752
| -8% | -$17.9K |
|
|
FPAY
3298
DELISTED
FlexShopper
FPAY
| $204K | ﹤0.01% |
159,480
-19,800
| -11% | -$19.2K |
|
3299
Five Point Holdings
FPH
$371M
| $204K | ﹤0.01% |
70,700
+44,395
| +169% | +$107K |
|
3300
Dogness International Corp
DOGZ
$16.8M
| $203K | ﹤0.01% |
13,930
-3,005
| -18% | -$47.8K |
|
Similar funds
Jim Simons's Q2 2023 Portfolio in Review
As of Q2 2023, Jim Simons held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Berkshire Hathaway Class A worth $316M.
- Jim Simons's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Jim Simons added most to Apple in Q2 2023, an estimated $856M increase.
- Jim Simons's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Jim Simons fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Jim Simons's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Jim Simons opened 541 new positions and closed 599 in Q2 2023.
- Jim Simons's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.